ES2409833T8 - Sal de dihidrógeno-fosfato de un antagonista del receptor D2 de prostaglandina - Google Patents

Sal de dihidrógeno-fosfato de un antagonista del receptor D2 de prostaglandina Download PDF

Info

Publication number
ES2409833T8
ES2409833T8 ES06825836T ES06825836T ES2409833T8 ES 2409833 T8 ES2409833 T8 ES 2409833T8 ES 06825836 T ES06825836 T ES 06825836T ES 06825836 T ES06825836 T ES 06825836T ES 2409833 T8 ES2409833 T8 ES 2409833T8
Authority
ES
Spain
Prior art keywords
prostaglandin
receptor antagonist
dihydrogen phosphate
phosphate salt
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06825836T
Other languages
English (en)
Other versions
ES2409833T3 (es
Inventor
Beverly Langevin
Edward Orton
Daniel Sherer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2409833T3 publication Critical patent/ES2409833T3/es
Publication of ES2409833T8 publication Critical patent/ES2409833T8/es
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES06825836T 2005-10-13 2006-10-12 Sal de dihidrógeno-fosfato de un antagonista del receptor D2 de prostaglandina. Active ES2409833T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72629005P 2005-10-13 2005-10-13
US726290P 2005-10-13
PCT/US2006/039901 WO2007047378A2 (en) 2005-10-13 2006-10-12 Dihydrogen phosphate salt of a prostaglandin d2 receptor antagonist

Publications (2)

Publication Number Publication Date
ES2409833T3 ES2409833T3 (es) 2013-06-28
ES2409833T8 true ES2409833T8 (es) 2013-09-26

Family

ID=37963090

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06825836T Active ES2409833T3 (es) 2005-10-13 2006-10-12 Sal de dihidrógeno-fosfato de un antagonista del receptor D2 de prostaglandina.

Country Status (35)

Country Link
US (1) US7642249B2 (es)
EP (1) EP1948620B1 (es)
JP (1) JP2009511591A (es)
KR (1) KR101365480B1 (es)
CN (1) CN101287714B (es)
AR (1) AR058085A1 (es)
AU (1) AU2006304187B2 (es)
BR (1) BRPI0617311A2 (es)
CA (1) CA2625563C (es)
CR (1) CR9870A (es)
DK (1) DK1948620T3 (es)
DO (2) DOP2006000220A (es)
EC (1) ECSP088362A (es)
ES (1) ES2409833T3 (es)
GT (1) GT200600457A (es)
HN (1) HN2008000603A (es)
HR (1) HRP20130341T1 (es)
IL (1) IL190673A (es)
MA (1) MA30005B1 (es)
MY (1) MY145648A (es)
NI (1) NI200800116A (es)
NO (1) NO20082072L (es)
NZ (1) NZ567433A (es)
PE (1) PE20070791A1 (es)
PL (1) PL1948620T3 (es)
PT (1) PT1948620E (es)
RS (1) RS52799B (es)
RU (1) RU2419614C2 (es)
SI (1) SI1948620T1 (es)
TN (1) TNSN08131A1 (es)
TW (1) TW200728288A (es)
UA (1) UA93062C2 (es)
UY (1) UY29862A1 (es)
WO (1) WO2007047378A2 (es)
ZA (1) ZA200802586B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2005000795A (es) * 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
DOP2007000068A (es) * 2006-04-12 2007-10-31 Sanofi Aventis Us Llc Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2
JP2009539881A (ja) * 2006-06-09 2009-11-19 アイコス コーポレイション Ｄｐ−２アンタゴニストとしての置換フェニル酢酸
ATE531699T1 (de) * 2007-06-29 2011-11-15 Sanofi Sa Verfahren zur herstellung von 2-(3-ä6-ä2-(2,4-
US8067445B2 (en) 2008-02-01 2011-11-29 Panmira Pharmaceuticals, Llc N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
US8497381B2 (en) 2008-02-25 2013-07-30 Panmira Pharmaceuticals, Llc Antagonists of prostaglandin D2 receptors
GB2463788B (en) * 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (en) 2008-10-01 2010-04-08 Amira Pharmaceuticals, Inc. Heteroaryl antagonists of prostaglandin d2 receptors
US8524748B2 (en) 2008-10-08 2013-09-03 Panmira Pharmaceuticals, Llc Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors
US20100112606A1 (en) * 2008-10-17 2010-05-06 Michael Armstrong Measurement and analysis of leukotrienes
AR074776A1 (es) * 2008-12-18 2011-02-09 Sanofi Aventis Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
WO2011014587A2 (en) 2009-07-31 2011-02-03 Amira Pharmaceuticals, Inc. Ophthalmic pharmaceutical compositions of dp2 receptor antagonists
KR20120047273A (ko) 2009-08-05 2012-05-11 판미라 파마슈티칼스, 엘엘씨 Ｄｐ2 길항제 및 이의 용도
EP2590640A1 (en) 2010-07-08 2013-05-15 Ramot at Tel-Aviv University Ltd Use of fts and analogs to treat non-autoimmune-allergic and non-allergic inflammatory conditions
EP2621276B1 (en) * 2010-09-30 2017-12-27 Merck Sharp & Dohme Corp. 2-alkoxy pyrimidine pde10 inhibitors
EP2912458B1 (en) 2012-10-24 2018-07-18 NYU Winthrop Hospital Non-invasive biomarker to identify subjects at risk of preterm delivery
JP6770522B2 (ja) 2015-02-13 2020-10-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 全身性エリテマトーデスを予防し、及び／又は、治療するためのｐｔｇｄｒ−１及び／又はｐｔｇｄｒ−２アンタゴニスト
DK3302448T3 (da) 2015-06-04 2024-02-05 Aurigene Oncology Ltd Erstattede heterocyclylafledninger som cdk-inhibitore
KR20200109293A (ko) 2017-09-13 2020-09-22 프로제너티, 인크. 자간전증 바이오마커 및 관련된 시스템 및 방법
WO2021113710A1 (en) 2019-12-04 2021-06-10 Progenity, Inc. Assessment of preeclampsia using assays for free and dissociated placental growth factor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711888A (en) * 1985-07-24 1987-12-08 Pfizer Inc. Hydroxy and alkoxy pyrimidines
ATE466581T1 (de) * 2001-12-07 2010-05-15 Vertex Pharma Verbindungen auf pyrimidin-basis als gsk-3-hemmer
KR100768609B1 (ko) * 2003-07-09 2007-10-18 에프. 호프만-라 로슈 아게 티오페닐아미노이미다졸린
HN2005000795A (es) 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2

Also Published As

Publication number Publication date
HRP20130341T1 (en) 2013-05-31
EP1948620A2 (en) 2008-07-30
HK1125133A1 (en) 2009-07-31
IL190673A (en) 2011-12-29
CA2625563C (en) 2011-04-19
DK1948620T3 (da) 2013-06-24
EP1948620B1 (en) 2013-03-20
PL1948620T3 (pl) 2013-08-30
SI1948620T1 (sl) 2013-05-31
CR9870A (es) 2008-06-18
DOP2006000223A (es) 2007-05-15
WO2007047378A2 (en) 2007-04-26
IL190673A0 (en) 2008-11-03
CA2625563A1 (en) 2007-04-26
RU2419614C2 (ru) 2011-05-27
MA30005B1 (fr) 2008-12-01
MY145648A (en) 2012-03-15
RS52799B (sr) 2013-10-31
NZ567433A (en) 2010-06-25
ECSP088362A (es) 2008-05-30
KR20080057275A (ko) 2008-06-24
UA93062C2 (ru) 2011-01-10
PT1948620E (pt) 2013-05-06
UY29862A1 (es) 2007-05-31
BRPI0617311A2 (pt) 2011-07-19
KR101365480B1 (ko) 2014-02-21
ZA200802586B (en) 2009-09-30
NI200800116A (es) 2011-12-15
JP2009511591A (ja) 2009-03-19
CN101287714B (zh) 2011-04-06
WO2007047378A3 (en) 2007-08-02
AU2006304187A1 (en) 2007-04-26
AU2006304187B2 (en) 2011-04-28
US7642249B2 (en) 2010-01-05
RU2008118491A (ru) 2009-11-20
US20080194600A1 (en) 2008-08-14
PE20070791A1 (es) 2007-08-16
TW200728288A (en) 2007-08-01
AR058085A1 (es) 2008-01-23
NO20082072L (no) 2008-05-02
HN2008000603A (es) 2010-11-03
DOP2006000220A (es) 2007-05-15
CN101287714A (zh) 2008-10-15
ES2409833T3 (es) 2013-06-28
TNSN08131A1 (en) 2009-07-14
GT200600457A (es) 2007-04-27

Similar Documents

Publication Publication Date Title
IL190673A0 (en) Dihydrogen phosphate salt of a prostaglandin d2 receptor antagonist
FR22C1030I1 (fr) Formes cristallines d'un inhibiteur de la prolyle hydroxylase
BRPI0913930A2 (pt) antagonistas de receptores de prostaglandinas d2
EP2854859A4 (en) CRYSTALLINE FORMS OF A BRUTON TYROSINE KINASE HEATHER
IL207130A (en) N'n'- Imaging Bacteria AminoalkylBiphenyl Antagonists of Prostaglandin Receptors 2d
BRPI0811000A2 (pt) Terapia de combinação com um composto agindo como inibidor de receptor de adp de plaqueta
ES2531422T8 (es) Generación de señales para señales binaurales
EP2573277A4 (en) FIXING DEVICE FOR HYDRAULIC TUBE OF A BUILDING MACHINE
BRPI0717937A2 (pt) Compostos de pirazona como antagonistas do receptor mineralocorticóide
GB2460597B (en) N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
LT2889043T (lt) Sintetiniai tarpiniai junginiai oligosacharido-baltymo konjugatų gamybai
IL213070A (en) A method for determining the efficacy of PD-1 antagonist
EP2199390A4 (en) ANTI-EPHA2 ANTIBODY
EP2245022A4 (en) ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
IL184816A0 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
IL196587A0 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
SMT201600084B (it) Sintesi del sale n4-(2,2-dimetil-4-[(diidrogeno fosfonossi)metil]-3-osso-5-pirido[1,4]ossazin-6-il)-5-fluoro-n2-(3,4,5-trimetossifenil)-2,4-pirimidindiammina disodio
BR112013023330A2 (pt) compostos de sulfonamida tendo atividade antagonista trpm8
EP2382416A4 (en) WEAR-PROOF SLUDGE TUBE
EP2249833A4 (en) PROGRUGS OF CGRP RECEPTOR ANTAGONISTS
BRPI0818902A2 (pt) Ciclopentanos substituídos tendo atividade de prostaglandina
ITPR20070098A1 (it) Procedimento per idratare un terreno coesivo mediante elettrosmosi perimpedirne la riduzione volumetrica per disidratazione
BRPI0806932A2 (pt) Antagonista do receptor s1p1 de cromeno
BRPI0818842A2 (pt) Síntese de compostos de sal quaternário.
FI20065708A0 (fi) Laitteisto yksillöllisesti muotoiltujen jalkineiden suunnittelemiseksi